[go: up one dir, main page]

WO1999058096A3 - Analogues de l'acide 2-phthalimidinoglutarique - Google Patents

Analogues de l'acide 2-phthalimidinoglutarique Download PDF

Info

Publication number
WO1999058096A3
WO1999058096A3 PCT/US1999/010287 US9910287W WO9958096A3 WO 1999058096 A3 WO1999058096 A3 WO 1999058096A3 US 9910287 W US9910287 W US 9910287W WO 9958096 A3 WO9958096 A3 WO 9958096A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
phthalimidinoglutaric
phthalimidinoglutaric acid
methyl
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/010287
Other languages
English (en)
Other versions
WO1999058096A2 (fr
WO1999058096A9 (fr
Inventor
Jamshed H Shah
Glenn M Swartz
Adonia E Papathanassiu
William E Fogler
John W Madsen
Shawn J Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Priority to AU41837/99A priority Critical patent/AU749356B2/en
Priority to EP99925585A priority patent/EP1091726A2/fr
Priority to JP2000547948A priority patent/JP2002514578A/ja
Priority to CA002331461A priority patent/CA2331461C/fr
Publication of WO1999058096A2 publication Critical patent/WO1999058096A2/fr
Publication of WO1999058096A3 publication Critical patent/WO1999058096A3/fr
Publication of WO1999058096A9 publication Critical patent/WO1999058096A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des analogues nouveaux et utiles de l'acide 2-phthalimidinoglutarique. Les analogues comprennent l'acide DL-2- méthyl-2- phthalimidinoglutarique et des analogues hydroxylés de 2-phthalimidinoglutarique. L'invention englobe également des procédés de fabrication de ces analogues. Elle concerne également les deux enantiomères de l'acide DL-2- méthyl-2- phthalimidinoglutarique, l'acide (R)-(+)-2- méthyl-2- phthalimidinoglutarique et l'acide (S)-(-)-2-méthyl-2-phthalimidinoglutarique ainsi que les procédés permettant de séparer ces énantiomères individuels du racémique vrai. De plus, cette invention, s'intéresse à des méthodes permettant d'inhiber l'angiogenèse et de traiter des affections en rapport avec l'angiogenèse, dont le cancer et la dégénérescence maculaire, par administration d'un ou de plusieurs de ces composés.
PCT/US1999/010287 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique Ceased WO1999058096A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41837/99A AU749356B2 (en) 1998-05-11 1999-05-11 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
EP99925585A EP1091726A2 (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique
JP2000547948A JP2002514578A (ja) 1998-05-11 1999-05-11 ２−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用
CA002331461A CA2331461C (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8503798P 1998-05-11 1998-05-11
US9738498P 1998-08-21 1998-08-21
US10803798P 1998-11-12 1998-11-12
US60/108,037 1998-11-12
US60/097,384 1998-11-12
US60/085,037 1998-11-12

Publications (3)

Publication Number Publication Date
WO1999058096A2 WO1999058096A2 (fr) 1999-11-18
WO1999058096A3 true WO1999058096A3 (fr) 2000-05-18
WO1999058096A9 WO1999058096A9 (fr) 2000-07-13

Family

ID=27374997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010287 Ceased WO1999058096A2 (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique

Country Status (6)

Country Link
EP (1) EP1091726A2 (fr)
JP (1) JP2002514578A (fr)
KR (1) KR100699968B1 (fr)
AU (1) AU749356B2 (fr)
CA (1) CA2331461C (fr)
WO (1) WO1999058096A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CN1731997A (zh) * 2002-10-31 2006-02-08 细胞基因公司 使用包含选择性细胞因子抑制药物的组合物治疗和控制黄斑变性的方法
US7973057B2 (en) 2003-09-17 2011-07-05 The United States Of America As Represented By The Department Of Health And Human Services Thalidomide analogs
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
CN104045594B (zh) * 2012-02-21 2016-08-17 四川大学 一类1,3-二氢-1-氧-2h-异吲哚类化合物及其用途
CN102603610B (zh) * 2012-02-21 2014-07-09 四川大学 1,3-二氢-1-氧-2h-异吲哚类化合物、其制备方法和用途
WO2015095052A1 (fr) * 2013-12-17 2015-06-25 Controlled Chemicals, Inc. Isoindolin-1-ones utilisées en tant qu'inhibiteurs du facteur inhibiteur de la migration des macrophages (mif)
CN109467550B (zh) * 2017-12-31 2022-02-18 苏州亚科科技股份有限公司 一种邻苯二甲酰胺基-l-谷氨酸酐的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese
EP0688771A1 (fr) * 1994-06-24 1995-12-27 Grünenthal GmbH Utilisation de composés lactames comme agents pharmaceutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese
EP0688771A1 (fr) * 1994-06-24 1995-12-27 Grünenthal GmbH Utilisation de composés lactames comme agents pharmaceutiques

Also Published As

Publication number Publication date
KR100699968B1 (ko) 2007-03-28
AU749356B2 (en) 2002-06-27
AU4183799A (en) 1999-11-29
WO1999058096A2 (fr) 1999-11-18
WO1999058096A9 (fr) 2000-07-13
EP1091726A2 (fr) 2001-04-18
KR20010052332A (ko) 2001-06-25
CA2331461C (fr) 2008-10-07
CA2331461A1 (fr) 1999-11-18
JP2002514578A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
WO2002064083A3 (fr) Synthese de 3-amino-thalidomide et de ses enantiomeres
EP4438114A3 (fr) Procédés de fabrication d'acide bempédoïque et compositions associées
CA2322204A1 (fr) 5-aminoindeno(1,2-c)-pyrazol-4-ones agents anticancereux et antiproliferatifs
WO2002076976A3 (fr) Inhibiteurs de rho-kinase
WO2002076977A3 (fr) Inhibiteurs de rho-kinase
WO2005018557A3 (fr) Pyridinones substitues
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
WO2000010507A3 (fr) Utilisation de melanine pour inhiber l'angiogenese et la degenerescence maculaire
WO2005046603A3 (fr) Composes pyridiniques
WO2002100347A3 (fr) Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
WO2005051304A3 (fr) Inhibiteurs de la proteine kinase akt
WO2004029045A3 (fr) Procede de preparation d'inhibiteurs quinazoline de rho-kinase et leurs intermediaires
CA2337991A1 (fr) Benzocycloheptenes, procede de production de ces composes preparations pharmaceutiques contenant ces composes et utilisation de ces composes pour la preparation de medicaments
WO1999058096A3 (fr) Analogues de l'acide 2-phthalimidinoglutarique
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
WO2002007669A3 (fr) Derives phospholipides de l'acide valproique et leurs melanges
CA2429133A1 (fr) Nouveaux derives imidazole, procede de production correspondant et utilisation de ces derives
WO2003007883A3 (fr) Acylsemicarbazides inhibiteurs de kinase dependant de la cycline utiles en tant qu'agents anticancereux et antiproliferatifs
HK1046902A1 (zh) 新型哌嗪基烷基硫代嘧啶衍生物，包含該衍生物的藥物組合物以及製備該活性物質的方法
WO2004073375A3 (fr) Derives de podophyllotoxine utiles comme agents antitumoraux
HK1046238A1 (zh) Calcilytic化合物
WO2006019685A3 (fr) Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides
EP1958939A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
WO2002016327A8 (fr) Benzimidazoles et analogues et utilisation de ces derniers comme inhibiteurs neutrophiles
IL156140A0 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2331461

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020007012550

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 547948

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 41837/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999925585

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999925585

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007012550

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 41837/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007012550

Country of ref document: KR